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CDC Issues Interim Recommendations for the Use of Influenza Antiviral 
Medications in the Setting of Oseltamivir Resistance among Circulating 
Influenza A (H1N1 ) Viruses, 
2008-09 Influenza Season
Although influenza activity is low in the United States to date, preliminary data from a limited number of states 
indicate that the prevalence of influenza A (H1N1) virus strains resistant to the antiviral medication oseltamivir is 
high. Therefore, CDC is issuing interim recommendations for antiviral treatment and chemoprophylaxis of 
influenza during the 2008-09 influenza season. When influenza A (H1N1) virus infection or exposure is 
suspected, zanamivir or a combination of oseltamivir and rimantadine are more appropriate options than 
oseltamivir alone. Local influenza surveillance data and laboratory testing can help with physician decision­
making regarding the choice of antiviral agents for their patients. The 2008-09 influenza vaccine is expected to be 
effective in preventing or reducing the severity of illness with currently circulating influenza viruses, including 
oseltamivir-resistant influenza A (H1N1) virus strains. Since influenza activity remains low and is expected to 
increase in the weeks and months to come, CDC recommends that influenza vaccination efforts continue.
Background
Influenza A viruses, including two subtypes (H1N1) and (H3N2), and influenza B viruses, currently circulate 
worldwide, but the prevalence of each can vary among communities and within a single community over the 
course of an influenza season. In the United States, four prescription antiviral medications (oseltamivir, zanamivir, 
amantadine and rimantadine) are approved for treatment and chemoprophylaxis of influenza. Since January 
2006, the neuraminidase inhibitors (oseltamivir, zanamivir) have been the only recommended influenza antiviral 
drugs because of widespread resistance to the adamantanes (amantadine, rimantadine) among influenza A 
(H3N2) virus strains. The neuraminidase inhibitors have activity against influenza A and B viruses while the 
adamantanes have activity only against influenza A viruses. In 2007-08, a significant increase in the prevalence of 
oseltamivir resistance was reported among influenza A (H1N1) viruses worldwide. During the 2007-08 influenza 
season, 10.9% of H1N1 viruses tested in the U.S. were resistant to oseltamivir.
Influenza activity has been low thus far this season in the United States. As of December 19, 2008, a limited 
number of influenza viruses isolated in the U.S. since October 1 have been available for antiviral resistance 
testing at CDC. Of the 50 H1N1 viruses tested to date from 12 states, 98% were resistant to oseltamivir, and all 
were susceptible to zanamivir, amantadine and rimantadine. Preliminary data indicate that oseltamivir-resistant 
influenza A (H1N1) viruses do not cause different or more severe symptoms compared to oseltamivir sensitive 
influenza A (H1N1) viruses. Influenza A (H3N2) and B viruses remain susceptible to oseltamivir. The proportion of 
influenza A (H1N1) viruses among all influenza A and B viruses that will circulate during the 2008-09 season 
cannot be predicted, and will likely vary over the course of the season and among communities. Oseltamivir- 
resistant influenza A (H1N1) viruses are antigenically similar to the influenza A (H1N1) virus strain represented in 
2008-09 influenza vaccine, and CDC recommends that influenza vaccination efforts continue as the primary 
method to prevent influenza.
Oseltamivir resistance among circulating influenza A (H1N1) virus strains presents challenges for the selection of 
antiviral medications for treatment and chemoprophylaxis of influenza, and provides additional reasons for 
clinicians to test patients for influenza virus infection and to consult surveillance data when evaluating persons
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with acute respiratory illnesses during influenza season. These interim guidelines provide options for treatment or 
chemoprophylaxis of influenza in the United States if oseltamivir-resistant H1N1 viruses are circulating widely in a 
community or if the prevalence of oseltamivir resistant H1N1 viruses is uncertain.
Interim Recommendations
Persons providing medical care for patients with suspected influenza or persons who are candidates for 
chemoprophylaxis against influenza should consider the following guidance for assessing and treating patients 
during the 2008-09 influenza season (see Table below). Guidance Table):
1) Review local or state influenza virus surveillance data weekly during influenza season, to determine which
types (A or B) and subtypes of influenza A virus (H3N2 or H1N1) are currently circulating in the area. For 
some communities, surveillance data might not be available or timely enough to provide information 
useful to clinicians.
2) Consider use of influenza tests that can distinguish influenza A from influenza B.
a. Patients testing positive for influenza B may be given either oseltamivir or zanamivir (no preference) if
treatment is indicated.
b. At this time, if a patient tests positive for influenza A, use of zanamivir should be considered if treatment
is indicated. Oseltamivir should be used alone only if recent local surveillance data indicate that 
circulating viruses are likely to be influenza A (H3N2) or influenza B viruses. Combination treatment 
with oseltamivir and rimantadine is an acceptable alternative, and might be necessary for patients 
that cannot receive zanamivir, (e.g., patient is <7 years old, has chronic underlying airways disease, 
or cannot use the zanamivir inhalation device), or zanamivir is unavailable. Amantadine can be 
substituted for rimantadine if rimantadine is unavailable.
c. If a patient tests negative for influenza, consider treatment options based on local influenza activity and
clinical impression of the likelihood of influenza. Because rapid antigen tests may have low sensitivity, 
treatment should still be considered during periods of high influenza activity for persons with 
respiratory symptoms consistent with influenza who test negative and have no alternative diagnosis. 
Use of zanamivir should be considered if treatment is indicated. Combination treatment with 
oseltamivir and rimantadine (substitute amantadine if rimantadine unavailable) is an acceptable 
alternative. Oseltamivir should be used alone only if recent local surveillance data indicates that 
circulating viruses are likely to be influenza A(H3N2) or influenza B viruses.
d. If available, confirmatory testing with a diagnostic test capable of distinguishing influenza caused by
influenza A (H1N1) virus from influenza caused by influenza A (H3N2) or influenza B virus can also 
be used to guide treatment. When treatment is indicated, influenza A (H3N2) and influenza B virus 
infections should be treated with oseltamivir or zanamivir (no preference). Influenza A (H1N1) virus 
infections should be treated with zanamivir or combination treatment with oseltamivir and rimantadine 
is an acceptable alternative.
3) Persons who are candidates for chemoprophylaxis (e.g., residents in an assisted living facility during an
influenza outbreak, or persons who are at higher risk for influenza-related complications and have had 
recent household or other close contact with a person with laboratory confirmed influenza) should be
provided with medications most likely to be effective against the influenza virus that is the cause of the 
outbreak, if known. Respiratory specimens from ill persons during institutional outbreaks should be 
obtained and sent for testing to determine the type and subtype of influenza A viruses associated with the 
outbreak and to guide antiviral therapy decisions. Persons whose need for chemoprophylaxis is due to 
potential exposure to a person with laboratory-confirmed influenza A (H3N2) or influenza B should 
receive oseltamivir or zanamivir (no preference). Zanamivir should be used when persons require 
chemoprophylaxis due to exposure to influenza A ( H1N1) virus. Rimantadine can be used if zanamivir 
use is contraindicated.
Enhanced surveillance for influenza antiviral resistance is ongoing at CDC in collaboration with local and state 
health departments. Clinicians should remain alert for additional changes in recommendations that might occur as 
the 2008--09 influenza season progresses. Oseltamivir resistant influenza A (H1N1) viruses are antigenically 
similar to the influenza A(H1N1) viruses represented in the vaccine, and vaccination should continue to be 
considered the primary prevention strategy regardless of oseltamivir sensitivity. Information on antiviral resistance 
will be updated in weekly surveillance reports (available at http://www.cdc.gov/flu/weekly/fluactivity.htm)
For more information on antiviral medications and additional considerations related to antiviral use during the 
2008-09 influenza season, visit http://www.cdc.gov/flu/professionals/antivirals/index.htm
TABLE
Interim recommendations for the selection of 
antiviral treatment using laboratory test results 
and viral surveillance data, United States, 2008-09
season
Rapid 
antigen or 
other 
laboratory 
test
Predominant 
virus(es) in 
community
Preferred
medication(s)
Alternative
(combination
antiviral
treatment)
Not done or 
negative, but 
clinical 
suspicion for 
influenza
H1N1 or 
unknown
Zanamivir Oseltamivir + 
Rimantadine*
Not done or 
negative, but 
clinical 
suspicion for 
influenza
H3N2 or B Oseltamivir or 
Zanamivir
None
Positive A H1N1 or 
unknown
Zanamivir Oseltamivir + 
Rimantadine*
Positive A H3N2 or B Oseltamivir or 
Zanamivir
None
Positive B Any Oseltamivir or 
Zanamivir
None
Positive
A+B**
H1N1 or 
unknown
Zanamivir Oseltamivir + 
Rimantadine*
Positive
A+B**
H3N2 or B Oseltamivir or 
Zanamivir
None
*Amantadine can be substituted for rimantadine but has increased risk of adverse events. Human data are lacking 
to support the benefits of combination antiviral treatment of influenza; however, these interim recommendations 
are intended to assist clinicians treating patients who might be infected with oseltamivir-resistant influenza A 
(H1N1) virus.
**Positive A+B indicates a rapid antigen test that cannot distinguish between influenza and influenza B viruses
Influenza antiviral medications used for treatment are most beneficial when initiated within the first two days of 
illness. Clinicians should consult the package insert of each antiviral medication for specific dosing information, 
approved indications and ages, contraindications/warnings/precautions, and adverse effects.
The Centers fo r Disease Control and Prevention (CDC) protects people's health and safety by preventing and 
controlling diseases and in juries; enhances health decisions by providing credible information on critical health 
issues; and promotes healthy living through strong partnerships with local, national and international
organizations.
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